glp-1compoundpharmacy

The formulation archive
Independent editorial information · not individual medical advice

Commercial pages may contain paid referral links. Compare the full payment terms and licensed-care details before enrollment.

This page contains affiliate links. We may earn a commission if you sign up through them, at no cost to you. All recommendations are independent.

Compounded Semaglutide Impurity Studies: The 2026 Independent Testing Round-Up

A handful of independent labs, university researchers, and pharmacy oversight groups have published testing data on compounded semaglutide over the past 18 months. The findings are less alarming than tabloid coverage suggests — but there are patterns worth knowing before you pick a pharmacy.

What Independent Testing Actually Looks For

When a lab tests a compounded semaglutide sample, it typically evaluates four things: potency (does the product actually contain the labeled amount of semaglutide?), identity (is it semaglutide at all, or a related peptide?), impurities (what else is in there, and at what levels?), and sterility (was it prepared under sterile conditions?). Each of these can fail independently — a product can be sterile and correctly identified but under-potent, for example.

Impurity Categories Reported

Reported impurities in compounded semaglutide fall into a few categories. Process-related impurities include leftover reagents from peptide synthesis. Related substances are semaglutide fragments or variants (des-amino forms, oxidation products, deamidation products). Excipient artifacts come from the formulation ingredients rather than the active. And in a small number of cases, contamination from unrelated peptides or non-peptide substances has been reported when API sourcing was compromised.

Most independent testing has found products that pass acceptable impurity thresholds. The problem cases — where impurities were above reasonable limits or where the wrong peptide was present entirely — have concentrated at a small number of pharmacies with poor API sourcing, not across the compounded market as a whole.

Embody

Injectable semaglutide — pricing varies

Injectable semaglutide only; a lead compounded-injectable option.

  • Injectable semaglutide focus
  • Standard 12-week titration
  • Direct-to-patient pharmacy shipping
FDA note: Compounded GLP-1 medications are not FDA-approved. Personalization must be based on a documented clinical need per current FDA guidance.
Compare current GLP-1 options →
Sponsored partner · Compounded and branded pathwaysGobyMeds

Explore the program’s treatment pathways and ask which medication type, pharmacy, enrollment requirements and recurring charges apply to your location.

Explore GobyMeds ↗Eligibility and prices must be verified directly. Compounded GLP-1 products are not FDA-approved.

Potency Findings

Potency variance is the most commonly reported issue. Reasonable target is ±10% of labeled potency. Some independent testing has found products at 85–95% of label (under-potent) and, less commonly, above 105% (over-potent). Under-potency at the low end is why some patients feel their compounded product "isn't working the same" as a brand-name equivalent — the actual delivered dose may be lower than expected.

Sponsored partner · Weight-management telehealthOak GLP-1

Review current treatment pathways, screening and follow-up, and clarify which medication and monthly charges apply.

Explore Oak GLP-1 ↗Eligibility and prices must be verified directly. Compounded GLP-1 products are not FDA-approved.
Sponsored partner · Compounded tirzepatide listingHealthRX — tirzepatide

Explore HealthRX’s compounded tirzepatide listing. Compounded medications are not FDA-approved; verify the current legal pathway, pharmacy and total price.

Explore HealthRX — tirzepatide ↗Eligibility and prices must be verified directly. Compounded GLP-1 products are not FDA-approved.

What Pharmacy Behavior Correlates With Better Results

Pharmacies that publish or share Certificates of Analysis on request tend to correlate with cleaner independent test results. So do pharmacies that name their API sources, participate in accreditation programs (PCAB, ACHC), and use third-party independent labs for potency verification (rather than only in-house testing).

If a pharmacy won't share a CoA on request, or if the CoA it shares is generic (not batch-specific), that's a data point worth weighing. Not disqualifying on its own, but worth stacking against other signals.

SPONSORED CARE OPTION

Sesame

Compare licensed-clinician services and ask about pharmacy sourcing, FDA-approved treatment options and itemized charges. Compounded medicines are not FDA-approved.

Pricing, medication access, service area and plan terms must be confirmed with the provider. This is not a drug-specific checkout link.

Explore Sesame program ↗

SHED

Starts lower, $399/mo at 7.5mg+

Note: SHED's price jumps to $399/mo once you titrate to 7.5mg or higher.

  • Lower entry pricing
  • Price jump at 7.5mg+
  • Compounded semaglutide + tirzepatide
FDA note: Compounded GLP-1 medications are not FDA-approved. Personalization must be based on a documented clinical need per current FDA guidance.
Compare current GLP-1 options →

How to Use Testing Data Without Overreacting

Independent testing findings are useful signal but shouldn't drive panic. Brand-name products also have specified impurity limits — the question is whether a compounded product meets reasonable standards, not whether it's identical to brand. For most patients on well-sourced compounded product, the difference is within margins that don't affect clinical outcome. For patients on poorly-sourced product, the differences can be meaningful enough to warrant switching.

Where to Start

Embody

Injectable semaglutide — pricing varies

Injectable semaglutide only; a lead compounded-injectable option.

  • Injectable semaglutide focus
  • Standard 12-week titration
  • Direct-to-patient pharmacy shipping
FDA note: Compounded GLP-1 medications are not FDA-approved. Personalization must be based on a documented clinical need per current FDA guidance.
Compare current GLP-1 options →

MadeMed

Oral tirzepatide ~$229/mo

Independent compounder offering compounded oral tirzepatide.

  • Compounded oral tirzepatide
  • $167–$229 range per dose tier
  • Direct pharmacy fulfillment
FDA note: Compounded GLP-1 medications are not FDA-approved. Personalization must be based on a documented clinical need per current FDA guidance.
Compare current GLP-1 options →

SHED

Starts lower, $399/mo at 7.5mg+

Note: SHED's price jumps to $399/mo once you titrate to 7.5mg or higher.

  • Lower entry pricing
  • Price jump at 7.5mg+
  • Compounded semaglutide + tirzepatide
FDA note: Compounded GLP-1 medications are not FDA-approved. Personalization must be based on a documented clinical need per current FDA guidance.
Compare current GLP-1 options →